AVINGER,INC. (NASDAQ:AVGR) Files An 8-K Results of Operations and Financial Condition

AVINGER,INC. (NASDAQ:AVGR) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 of the Original Filing is hereby replaced in its
entirety by the disclosure under Item 2.02 of this Amendment. No
other changes have been made to the Original Filing.

Item 2.02. Results of Operations and
Financial Condition.

On March6, 2017, the Company issued a press release regarding its
financial results for the quarter and full year ended December31,
2016 (the Earnings Release), which was furnished as an exhibit to
the Companys Current Report on Form8-K filed on March6, 2017. The
Company is hereby reissuing the Earnings Release to conform
certain balance sheet information to that provided for in the
Companys Form10-K for the year ended December31, 2016 to be filed
on March14, 2017. A copy of the updated Earnings Release is
furnished as Exhibit99.1 to this Form8-K/A. All other information
in the Original Filing remains unchanged.

This information is intended to be furnished under Item 2.02 of
Form8-K and shall not be deemed filed for purposes of Section18
of the Securities Exchange Act of 1934, as amended (the Exchange
Act), or incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act, except
as shall be expressly set forth by specific reference in such a

Item 9.01. Financial Statements and





Press Release of Avinger,Inc. dated March6, 2017.


Avinger, Inc. is a commercial-stage medical device company. The Company designs, manufactures and sells image-guided, catheter-based systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Company focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Company manufactures and sells a suite of products in the United States and certain European markets. The Company’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

AVINGER, INC. (NASDAQ:AVGR) Recent Trading Information

AVINGER, INC. (NASDAQ:AVGR) closed its last trading session 00.00 at 2.05 with 94,797 shares trading hands.

An ad to help with our costs